Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | MRD determinations in venetoclax treatment of CLL

Nicolas Martinez-Calle • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Nicolas Martinez-Calle, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses minimal residual disease (MRD) determinations in venetoclax treatment of heavily pre-treated chronic lymphocytic leukemia (CLL) patients. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Nicolas Martinez-Calle

3:17
Treating CLL in the UK: current and future outlooks
Nicolas Martinez-Calle • 11 Jun 2023
2:40
EPIC update: observational study of first-line acalabrutinib treatment for CLL
Nicolas Martinez-Calle • 11 Jun 2023
6:28
Outcomes following first-line therapy in routine clinical practice in ALCL
Nicolas Martinez-Calle • 14 May 2020
9:35
Outcomes of older patients with primary CNS lymphoma
Nicolas Martinez-Calle • 14 May 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals